Related references
Note: Only part of the references are listed.HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
Diana P. English et al.
MOLECULAR DIAGNOSIS & THERAPY (2013)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
Alessandra Fabi et al.
CLINICAL CANCER RESEARCH (2011)
Reproducibility in the diagnosis of needle core biopsies of non-palpable breast lesions: an international study using virtual slides published on the world-wide web
Francesco Alfredo Zito et al.
HISTOPATHOLOGY (2010)
Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells
AnLi Zhang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
External Quality Assurance of HER2 FISH and ISH Testing Three Years of the UK National External Quality Assurance Scheme
John M. S. Bartlett et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review
Yolanda Madarnas et al.
CANCER TREATMENT REVIEWS (2008)
The need for a quality control of the whole process of immunohistochemistry human epidermal growth factor receptor 2/neu determination: A united kingdom national external quality assessment Service/Italian network for quality assessment of tumor biomarkers pilot experience
Angelo Paradiso et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T)
K. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer
K. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Standardization of HER2 testing:: results of an international proficiency-testing ring study
Mitch Dowsett et al.
MODERN PATHOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Updated recommendations for HER2 testing in the UK
IO Ellis et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)